Contineum Therapeutics (CTNM) Assets Average (2024 - 2026)

Contineum Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $255.9 million for Q2 2026.

• In Q2 2026, Assets Average rose 34.26% year-over-year to $255.9 million; the TTM figure through Jun 2026 stood at $255.9 million (up 34.26% YoY), while the FY2025 annual figure was $244.7 million, up 42.61% from the prior year.
• Assets Average for Q2 2026 stood at $255.9 million, down from $269.0 million in the prior quarter.
• The five-year high for Assets Average was $269.0 million in Q1 2026, with the low at $127.0 million in Q1 2024.
• The 3-year median for Assets Average is $210.0 million (2024), against an average of $207.4 million.
• Peak annual rise in Assets Average reached 61.89% in 2025, while the deepest fall reached 14.55% in 2025.
• Contineum Therapeutics' Assets Average stood at $214.4 million in 2024, then climbed by 9.0% to $233.7 million in 2025, then rose by 9.46% to $255.9 million in 2026.
• Business Quant data shows CTNM's Assets Average at $255.9 million in Q2 2026, $269.0 million in Q1 2026, and $233.7 million in Q4 2025.